Idiopathic hypersomniaNews & Research
15 curated articles for Idiopathic hypersomnia — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- Sleep Apr 16, 2026
Perspectives on idiopathic hypersomnia: diagnostic challenges, unknown pathophysiological, and emerging therapeutic strategies.
Idiopathic hypersomnia is a rare chronic neurological condition that may be characterized by excessive daytime sleepiness, and/or prolonged nocturnal sleep, and also sleep inertia, yet its underlying mechanisms and diagnostic boundaries remain poorly defined. A key challenge is distinguishing excess...
Why it matters: Recent peer-reviewed research on Idiopathic hypersomnia that may be relevant for patients and caregivers.
- Sleep Apr 16, 2026
Sleep time and SOREMPs features support idiopathic hypersomnia and narcolepsy type 2 as a single disease entity.
Idiopathic hypersomnia (IH) and narcolepsy type 2 (NT2) are rare hypersomnolence disorders with unknown pathophysiology. Recent evidence suggests they may belong to the same spectrum. This study compared objective sleep duration and REM sleep features, including sleep-onset REM periods (SOREMPs), du...
Why it matters: Recent peer-reviewed research on Idiopathic hypersomnia that may be relevant for patients and caregivers.
- Journal of sleep research Mar 20, 2026
Age at Onset and Delays in Diagnosis of Central Disorders of Hypersomnolence Over the Past 30 Years.
Patients with narcolepsy type 1 (NT1), type 2 (NT2), idiopathic hypersomnia (IH) usually suffer from symptoms for years, even decades, before being diagnosed. We aimed to assess age at onset, age at diagnosis and changes in the diagnostic delays of these patients from 1990 to 2020 in a single centre...
Why it matters: Recent peer-reviewed research on Idiopathic hypersomnia that may be relevant for patients and caregivers.
- Journal of sleep research Mar 20, 2026
Dynamic Functional Network Connectivity Patterns Distinguish Neurobiological Substrates of Narcolepsy Type 1 and Idiopathic Hypersomnia: Potential Biomarkers From Resting-State fMRI.
This study aimed to explore dynamic functional network connectivity (dFNC) differences between narcolepsy type 1 (NT1), idiopathic hypersomnia (IH), and healthy controls (HCs), and evaluate the potential of dFNC as a neurobiological marker for differentiating these hypersomnolent disorders. We recru...
Why it matters: Recent peer-reviewed research on Idiopathic hypersomnia that may be relevant for patients and caregivers.
- Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine Mar 19, 2026
Correction to: Clinical and polysomnographic changes in idiopathic hypersomnia ten years after the diagnosis.
Correction to: Clinical and polysomnographic changes in idiopathic hypersomnia ten years after the diagnosis.
Why it matters: Recent peer-reviewed research on Idiopathic hypersomnia that may be relevant for patients and caregivers.
- CNS drugs Mar 14, 2026
Effectiveness and Safety of Low-Sodium Oxybate in Participants with Idiopathic Hypersomnia: Primary Results from the DUET Study.
Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) was a phase 4, prospective, multicenter, single-arm, open-label, multiple-cohort study of individuals with idiopathic hypersomnia or narcolepsy evaluating safety and effectiveness of low-sodium oxybate (LXB; Xyw...
Why it matters: Recent peer-reviewed research on Idiopathic hypersomnia that may be relevant for patients and caregivers.
- Sleep Mar 11, 2026
Depressive symptoms and suicidal thoughts in idiopathic hypersomnia: a cross-sectional and longitudinal study.
To assess the frequency and factors associated with depressive symptoms, major depressive episode (MDE), suicidal thoughts, and risk in patients with idiopathic hypersomnia (IH), a rare hypersomnolence disorder, compared to controls, and to evaluate their changes after management. Consecutive untrea...
Why it matters: Recent peer-reviewed research on Idiopathic hypersomnia that may be relevant for patients and caregivers.
- Sleep Mar 11, 2026
Narcolepsy type 2 is an unstable diagnosis and idiopathic hypersomnia has the potential for remission-long-term and cross-sectional observations from the Bern Sleep-Wake Registry.
The boundaries between narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) and the evolution of these diseases over time are poorly understood. This retrospective cohort single-center study with a cross-sectional follow-up aims to assess changes of diagnosis and test fi...
Why it matters: Recent peer-reviewed research on Idiopathic hypersomnia that may be relevant for patients and caregivers.
- Sleep Mar 11, 2026
Classification and clustering on nocturnal polysomnography: distinctions and overlaps between central disorders of hypersomnolence.
Differential diagnosis of narcolepsy type 2 (NT2) from type 1 (NT1) and idiopathic hypersomnia (IH) is challenging due to overlapping symptoms. We developed an automated method using nocturnal polysomnography (nPSG) data to differentiate these conditions and clinical controls (CCs), and explored var...
Why it matters: Recent peer-reviewed research on Idiopathic hypersomnia that may be relevant for patients and caregivers.
- Sleep Feb 28, 2026
Homeostatic dysregulation of slow wave activity during sleep in Idiopathic Hypersomnia.
Sleep homeostasis describes the accumulation of sleep pressure during wakefulness and its dissipation during sleep. Electroencephalographic delta power (SWA, [0.5-4Hz]) is a known marker of sleep pressure. Dysregulation of this process has been proposed in idiopathic hypersomnia (IH), a debilitating...
Why it matters: Recent peer-reviewed research on Idiopathic hypersomnia that may be relevant for patients and caregivers.
- Sleep medicine Feb 21, 2026
Intelligence quotient in adults with idiopathic hypersomnia and narcolepsy type 1.
Given that intelligence quotient (IQ) has not previously been assessed in idiopathic hypersomnia (IH) and only rarely in adults with narcolepsy type 1 (NT1), this study examined IQ in adults with IH and NT1. The Wechsler Adult Intelligence Scale-Fourth Edition (WAIS-IV), comprising the Full Scale IQ...
Why it matters: Recent peer-reviewed research on Idiopathic hypersomnia that may be relevant for patients and caregivers.
- Sleep medicine clinics Feb 20, 2026
Disparities in Diagnosis of and Management of Narcolepsy and Idiopathic Hypersomnia.
This article examines disparities in the diagnosis, treatment, and lived experience of narcolepsy and idiopathic hypersomnia (IH). It highlights prolonged diagnostic delays, especially in women, children, and marginalized groups, compounded by limited access to essential sleep tests and insurance-re...
Why it matters: Recent peer-reviewed research on Idiopathic hypersomnia that may be relevant for patients and caregivers.
- Journal of sleep research Jan 30, 2026
Impact of Cannabis Smoking on Multiple Sleep Latency Test Outcomes.
Our purpose was to evaluate how cannabis smoking influenced multiple sleep latency test (MSLT) outcomes. This was a retrospective study of all adults that had undergone a MSLT at St. Michael's Hospital (Toronto, Ontario, Canada) from 1 January 2008 until 31 December 2018. Three groups of persons wer...
Why it matters: Recent peer-reviewed research on Idiopathic hypersomnia that may be relevant for patients and caregivers.
- Sleep medicine Jan 26, 2026
Clinical and socioeconomic burden among people with narcolepsy or idiopathic hypersomnia: A retrospective cohort analysis of the Danish National Patient Registry.
To assess the clinical and socioeconomic burden of narcolepsy and idiopathic hypersomnia (IH) in Denmark. This retrospective cohort study using Danish National Patient Registry data included individuals diagnosed with narcolepsy or IH (1/1/2005-12/31/2017). Individuals with narcolepsy were matched 1...
Why it matters: Recent peer-reviewed research on Idiopathic hypersomnia that may be relevant for patients and caregivers.
- Sleep medicine Jan 2, 2026
Effects of low-sodium oxybate on diary-based sleep time in a clinical study in adults with idiopathic hypersomnia.
Prolonged nighttime sleep is a prominent symptom in many patients with idiopathic hypersomnia. The only US Food and Drug Administration-approved treatment for idiopathic hypersomnia is low-sodium oxybate (LXB; Xywav®), for which efficacy and safety were established in a double-blind, placebo-co...
Why it matters: Recent peer-reviewed research on Idiopathic hypersomnia that may be relevant for patients and caregivers.
More on Idiopathic hypersomnia
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.